Citation:Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al 2014

Citation

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014 Nov 13;371(20):1877-88 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25265492.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al 2014	Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?	Meghna Kakani	completed
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al 2014 2	Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?	Cecilia Taing	completed

Compare quality appraisals for each clinical question

• [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|]] (compare critical appraisals)
• [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|]] (compare critical appraisals)

Cited by

1. Targeted therapies for melanoma